These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 3473688)

  • 21. [Cytosine arabinoside and VM-26 in induction treatment, failures and recurrences of childhood acute lymphoblastic leukemias].
    Navajas Gutiérrez A; Bezanilla Regato JL; Moya Calderón E; Piñán MA
    An Esp Pediatr; 1988 Oct; 29 Suppl 34():91-3. PubMed ID: 3214046
    [No Abstract]   [Full Text] [Related]  

  • 22. High-dose cytosine arabinoside with amsacrine for treatment of acute lymphoblastic leukemia.
    Arlin ZA
    J Clin Oncol; 1986 Dec; 4(12):1868. PubMed ID: 3465878
    [No Abstract]   [Full Text] [Related]  

  • 23. [Acute refractory lymphoblastic leukemia in the adult. Treatment with daunorubicin, cytosine arabinoside, 6-thioguanine, vincristine and prednisone].
    Marín P; Grañena A; Carreras E; Ribera JM; Rozman C
    Sangre (Barc); 1984; 29(6):987-92. PubMed ID: 6598237
    [No Abstract]   [Full Text] [Related]  

  • 24. Total-body irradiation and high-dose teniposide: a pilot study in bone marrow transplantation for patients with relapsed acute lymphoblastic leukemia.
    Krance RA; Forman SJ; Blume KG
    Cancer Treat Rep; 1987 Jun; 71(6):645-7. PubMed ID: 3555790
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II evaluation of teniposide and ifosfamide in refractory adult acute lymphocytic leukemia: a Southwest Oncology Group Study.
    Ryan DH; Kopecky KJ; Head D; Gumbart CN; Grever MR; Karanes C; Weick JK; Coltman CA
    Cancer Treat Rep; 1987; 71(7-8):713-6. PubMed ID: 3475171
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [A case of refractory acute lymphocytic leukemia responded to an intermediate-dose of cytosine arabinoside (ID Ara-C) therapy].
    Hirota Y; Shibuya T; Ohhara N; Okamura S; Iwagiri R; Tada Y; Otsuka T; Nagano M; Tsuda Y; Niho Y
    Rinsho Ketsueki; 1986 Jun; 27(6):941-6. PubMed ID: 3463812
    [No Abstract]   [Full Text] [Related]  

  • 27. VP 16-213 and cytosine-arabinoside combination chemotherapy for refractory acute lymphoblastic leukemia in adults.
    Morra E; Lazzarino M; Alessandrino EP; Inverardi D; Canevari A; Bernasconi C
    Eur J Cancer Clin Oncol; 1984 Dec; 20(12):1471-5. PubMed ID: 6594241
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Etoposide and teniposide in the treatment of acute leukemia.
    Björkholm M
    Med Oncol Tumor Pharmacother; 1990; 7(1):3-10. PubMed ID: 2187120
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Phase I trial and pharmacokinetics of VM 26 combined with cisplatin administered by the intraperitoneal route without mixing time].
    Chatelut E; Canal P; De Forni M; Chevreau C; Houin G; Bugat R
    Bull Cancer; 1989; 76(8):893-6. PubMed ID: 2620120
    [No Abstract]   [Full Text] [Related]  

  • 30. Sequential high-dose cytosine arabinoside and L-asparaginase in childhood leukemia in relapse.
    Ettinger LJ; Biener R; Finklestein JZ; Kamalakar P; Jones GR; Avramis VI; Holcenberg JS
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):155-9. PubMed ID: 3859930
    [No Abstract]   [Full Text] [Related]  

  • 31. Experience with intermediate- and high-dose cytosine arabinoside in relapsed and refractory acute leukaemia.
    Willemze R; Fibbe WE; Zwaan FE
    Neth J Med; 1983; 26(8):215-9. PubMed ID: 6580554
    [No Abstract]   [Full Text] [Related]  

  • 32. [Adult acute lymphoblastic leukemia: preliminary results of the LAL-86 protocol].
    Ribera JM; Grañena A; Rozman C; Urbano-Ispizua A; Bladé J; Carreras E; Cervantes F; Marín P; Sierra J; Nomdedeu B
    Sangre (Barc); 1990 Feb; 35(1):26-32. PubMed ID: 2333581
    [TBL] [Abstract][Full Text] [Related]  

  • 33. VM26 therapy in children with drug-refractory lymphocytic leukemia.
    Rivera G; Dahl GV; Murphy SB; Bowman WP; Aur RJ; Avery TL; Simone JV
    Cancer Chemother Pharmacol; 1982; 7(2-3):169-72. PubMed ID: 7083458
    [No Abstract]   [Full Text] [Related]  

  • 34. Intensive retreatment of childhood acute lymphoblastic leukemia in first bone marrow relapse. A Pediatric Oncology Group Study.
    Rivera GK; Buchanan G; Boyett JM; Camitta B; Ochs J; Kalwinsky D; Amylon M; Vietti TJ; Crist WM
    N Engl J Med; 1986 Jul; 315(5):273-8. PubMed ID: 3523250
    [TBL] [Abstract][Full Text] [Related]  

  • 35. VM-26 with prednisone and vincristine for treatment of refractory acute lymphocytic leukemia.
    Rivera G; Bowman WP; Murphy SB; Dahl GV; Aur RJ; Kalwinsky DK; Wood A; Stagner S; Avery TL
    Med Pediatr Oncol; 1982; 10(5):439-46. PubMed ID: 6958957
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I-II trial of VM-26 (NSC-122819) in the treatment of children with late-stage leukemia.
    Rosenstock JG; Donaldson MH
    Cancer Treat Rep; 1976 Mar; 60(3):265-7. PubMed ID: 1063066
    [No Abstract]   [Full Text] [Related]  

  • 37. Phase II study of VM-26 in acute leukemia, neuroblastoma, and other refractory childhood malignancies: a report from the Children's Cancer Study Group.
    Bleyer WA; Krivit W; Chard RL; Hammond D
    Cancer Treat Rep; 1979 Jun; 63(6):977-81. PubMed ID: 380803
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical trials of teniposide (VM-26) in childhood acute lymphocytic leukemia.
    Rivera GK; Evans WE
    Semin Oncol; 1992 Apr; 19(2 Suppl 6):51-8. PubMed ID: 1411639
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modulation of cytosine arabinoside (ara-C) and high-dose ara-C in acute leukemia.
    Zittoun R; Marie JP; Zittoun J; Marquet J; Haanen C
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):139-43. PubMed ID: 3859928
    [No Abstract]   [Full Text] [Related]  

  • 40. [Hypersensitivity to VM-26].
    Köster B; Ritter J; Bode U
    Klin Padiatr; 1984; 196(3):178-80. PubMed ID: 6540829
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.